Report cover image

Infectious Disease Point-of-care (POC) Diagnostics Market

Publisher Fortune Business Insights Pvt. Ltd.
Published Oct 01, 2024
Length 180 Pages
SKU # FOB19260684

Description

Infectious Disease Point-of-care (POC) Diagnostics Market



Growth Factors of Infectious Disease Point-of-care (POC) Diagnostics Market

The Infectious Disease Point-of-care (POC) Diagnostics market size was valued at USD 15.81 billion in 2023, and the market is now projected to grow from USD 15.21 billion in 2024 to USD 12.46 billion by 2032, exhibiting a CAGR of -2.8% during the forecast period of 2024-2032.

In the havoc of the widespread the Infectious disease point-of-care diagnostics market growth was largely influenced globally as the pharmaceutical companies and institutes for research had a deep focus on the patients attacked by the coronavirus and their diagnosis and treatments. The presentation of progressed items and speedy turnaround time units boosted the advertise development within the estimate timeframe.

In spite of the colossal endeavors put into overseeing irresistible infections, the improvement of low-cost, exact, and touchy POC items is in enormous request. Nanotechnology has opened the entryways for far reaching applications within the healthcare industry. Researchers over the globe have emphasized the presentation of nanoparticle-based and nano-device-based POC stages and tests.

With reference to the advantages such as speedy turnaround time and the capacity to form quick treatment choices, POC conclusion has gotten to be a pivotal portion of patient-centric healthcare. There has been a particular move from centralized to decentralized point-of-care testing for irresistible illnesses, progressing patient care. The developing request for fast tests has energized the showcase players to supply POC items to decentralized areas, subsequently driving this marketplace.

Comprehensive Analysis of Infectious Disease Point-of-care (POC) Diagnostics Market

On the technique basis, the market structure is sub parted as atomic diagnostics, horizontal stream immunoassay, agglutination test and the Immuno-concentration/ flow through measure. On the bifurcation of the disease segment basis, the market arena is portioned into tuberculosis, hepatitis B infection, influenza, HIV, clostridium difficile infections (CDI), pneumonia/streptococcus-associated contaminations, hepatitis C infection, respiratory syncytial infection, MRSA and others. The worldwide frequency rate of irresistible illnesses and rising beneath conclusion burden has brought about within the quick appropriation of POC testing packs. The market arena on the division of end-user basis is further fragmented as nursing homes, critical care & retail clinics, healing center bedside, physician's office labs, domestic & self-testing and others.

The territorial area of North America is stated to made a leading impact on the worldwide infectious disease point-of-care (POC) diagnostics market share with a globally impressive valuation of USD 5.68 billion in the projected timeframe. The leading attribute of this territory is inferable to the expanding appropriation of progressed point-of-care diagnostics for the location of different irresistible illnesses.

The market for infectious disease point-of-care diagnostics is semi-consolidated owing to the solid item portfolios and surprising dispersion arrange of major companies in created and rising nations. The operating players such as F. Hoffmann-La Roche AG (Switzerland), Cepheid Inc. (U.S.), BD (U.S.), Thermofisher Scientific Inc. (U.S.), Quest Diagnostics Incorporated (U.S.), Quidel Corporatio (U.S.), Trinity Biotech (Ireland), Cardinal Health Inc. (U.S.), and Abbott (U.S.) Research facilities lead the advertise, accounting for a major market impression over the globe.

In between the month of February 2022, the Trinity Biotech company received endorsement for its TrinScreen HIV, an HIV screening item, from the World Health Organization (WHO). It may be a fast test giving comes about in less than 12 minutes from a finger adhere drop of blood.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2030

Base Year 2022

Estimated Year 2023

Forecast Period 2023-2030

Historical Period 2019-2021

Unit Value (USD Billion)

Growth Rate CAGR of -2.8% from 2023-2030

Segmentation By Technique

Lateral Flow Immunoassay (LFIA)

Agglutination Test

Flow-through test/Immunoconcentration Assay

Molecular Diagnostics

Others

By Disease

HIV

Hepatitis B Virus

Pneumonia/Streptococcus Associated Infections

Respiratory Syncytial Virus (RSV)

Influenza

Clostridium Difficile Infections (CDI)

Hepatitis C Virus

Methicillin-Resistant Staphylococcus Aureus (MRSA)

Tuberculosis (TB)

COVID-19

Others

By End-User

Hospital Bedside

Physician's Office Lab

Urgent Care & Retail Clinics

Home & Self-testing

Nursing Home

Others

By Geography

North America (U.S. and Canada)

Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)

Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)

Latin America (Brazil, Mexico, and Rest of Latin America)

Middle East & Africa (South Africa, GCC and Rest of the Middle East & Africa)

Table of Contents

180 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Prevalence of Key Infectious Diseases, By Key Countries, 2022
4.2. New Product Launches
4.3. Key Industrial Developments (Mergers, Acquisitions, Partnerships, etc.)
4.4. Technological Advancements in Infectious Disease Point of Care (POC) Diagnostics
4.5. Impact of COVID-19 on Infectious Disease Point of Care (POC) Diagnostics Market
4.6. Overview of Initiatives for Infectious Disease Point of Care (POC) Diagnostics in Emerging Countries
4.7. Pricing Analysis of Various Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
4.8. Analysis of Product Features of Key Infectious Disease Point of Care (POC) Diagnostics, By Key Companies
5. Global Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2019-2030
5.1. Market Analysis, Insights and Forecast – By Technique
5.1.1. Lateral Flow Immunoassay (LFIA)
5.1.2. Agglutination Tests
5.1.3. Flow-through Tests / Immunoconcentration Assays
5.1.4. Molecular Diagnostics
5.1.5. Others
5.2. Market Analysis, Insights and Forecast – By Disease
5.2.1. Human Immunodeficiency Virus (HIV)
5.2.2. Hepatitis B Virus (HBV)
5.2.3. Pneumonia / Streptococcus Associated Infections
5.2.4. Respiratory Syncytial Virus (RSV)
5.2.5. Influenza
5.2.6. Clostridium difficile infection (CDI)
5.2.7. Hepatitis C Virus (HCV)
5.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
5.2.9. Tuberculosis (TB)
5.2.10. COVID-19
5.2.11. Others
5.3. Market Analysis, Insights and Forecast – By End User
5.3.1. Hospital Bedside
5.3.2. Physician's Office Lab
5.3.3. Urgent Care & Retail Clinics
5.3.4. Home & Self-Testing
5.3.5. Nursing Homes
5.3.6. Others
5.4. Market Analysis, Insights and Forecast – By Geography
5.4.1. North America
5.4.2. Europe
5.4.3. Asia Pacific
5.4.4. Latin America
5.4.5. Middle East & Africa
6. North America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2019-2030
6.1. Market Analysis, Insights and Forecast – By Technique
6.1.1. Lateral Flow Immunoassay (LFIA)
6.1.2. Agglutination Tests
6.1.3. Flow-through Tests / Immunoconcentration Assays
6.1.4. Molecular Diagnostics
6.1.5. Others
6.2. Market Analysis, Insights and Forecast – By Disease
6.2.1. Human Immunodeficiency Virus (HIV)
6.2.2. Hepatitis B Virus (HBV)
6.2.3. Pneumonia / Streptococcus Associated Infections
6.2.4. Respiratory Syncytial Virus (RSV)
6.2.5. Influenza
6.2.6. Clostridium difficile infection (CDI)
6.2.7. Hepatitis C Virus (HCV)
6.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
6.2.9. Tuberculosis (TB)
6.2.10. COVID-19
6.2.11. Others
6.3. Market Analysis, Insights and Forecast – By End User
6.3.1. Hospital Bedside
6.3.2. Physician's Office Lab
6.3.3. Urgent Care & Retail Clinics
6.3.4. Home & Self-Testing
6.3.5. Nursing Homes
6.3.6. Others
6.4. Market Analysis, Insights and Forecast – By Country
6.4.1. U.S.
6.4.2. Canada
7. Europe Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2019-2030
7.1. Market Analysis, Insights and Forecast – By Technique
7.1.1. Lateral Flow Immunoassay (LFIA)
7.1.2. Agglutination Tests
7.1.3. Flow-through Tests / Immunoconcentration Assays
7.1.4. Molecular Diagnostics
7.1.5. Others
7.2. Market Analysis, Insights and Forecast – By Disease
7.2.1. Human Immunodeficiency Virus (HIV)
7.2.2. Hepatitis B Virus (HBV)
7.2.3. Pneumonia / Streptococcus Associated Infections
7.2.4. Respiratory Syncytial Virus (RSV)
7.2.5. Influenza
7.2.6. Clostridium difficile infection (CDI)
7.2.7. Hepatitis C Virus (HCV)
7.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
7.2.9. Tuberculosis (TB)
7.2.10. COVID-19
7.2.11. Others
7.3. Market Analysis, Insights and Forecast – By End User
7.3.1. Hospital Bedside
7.3.2. Physician's Office Lab
7.3.3. Urgent Care & Retail Clinics
7.3.4. Home & Self-Testing
7.3.5. Nursing Homes
7.3.6. Others
7.4. Market Analysis, Insights and Forecast – By Country/Sub-region
7.4.1. U.K.
7.4.2. Germany
7.4.3. France
7.4.4. Spain
7.4.5. Italy
7.4.6. Scandinavia
7.4.7. Rest of Europe
8. Asia Pacific Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2019-2030
8.1. Market Analysis, Insights and Forecast – By Technique
8.1.1. Lateral Flow Immunoassay (LFIA)
8.1.2. Agglutination Tests
8.1.3. Flow-through Tests / Immunoconcentration Assays
8.1.4. Molecular Diagnostics
8.1.5. Others
8.2. Market Analysis, Insights and Forecast – By Disease
8.2.1. Human Immunodeficiency Virus (HIV)
8.2.2. Hepatitis B Virus (HBV)
8.2.3. Pneumonia / Streptococcus Associated Infections
8.2.4. Respiratory Syncytial Virus (RSV)
8.2.5. Influenza
8.2.6. Clostridium difficile infection (CDI)
8.2.7. Hepatitis C Virus (HCV)
8.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
8.2.9. Tuberculosis (TB)
8.2.10. COVID-19
8.2.11. Others
8.3. Market Analysis, Insights and Forecast – By End User
8.3.1. Hospital Bedside
8.3.2. Physician's Office Lab
8.3.3. Urgent Care & Retail Clinics
8.3.4. Home & Self-Testing
8.3.5. Nursing Homes
8.3.6. Others
8.4. Market Analysis, Insights and Forecast – By Country/Sub-region
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. Southeast Asia
8.4.6. Rest of Asia Pacific
9. Latin America Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2019-2030
9.1. Market Analysis, Insights and Forecast – By Technique
9.1.1. Lateral Flow Immunoassay (LFIA)
9.1.2. Agglutination Tests
9.1.3. Flow-through Tests / Immunoconcentration Assays
9.1.4. Molecular Diagnostics
9.1.5. Others
9.2. Market Analysis, Insights and Forecast – By Disease
9.2.1. Human Immunodeficiency Virus (HIV)
9.2.2. Hepatitis B Virus (HBV)
9.2.3. Pneumonia / Streptococcus Associated Infections
9.2.4. Respiratory Syncytial Virus (RSV)
9.2.5. Influenza
9.2.6. Clostridium difficile infection (CDI)
9.2.7. Hepatitis C Virus (HCV)
9.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
9.2.9. Tuberculosis (TB)
9.2.10. COVID-19
9.2.11. Others
9.3. Market Analysis, Insights and Forecast – By End User
9.3.1. Hospital Bedside
9.3.2. Physician's Office Lab
9.3.3. Urgent Care & Retail Clinics
9.3.4. Home & Self-Testing
9.3.5. Nursing Homes
9.3.6. Others
9.4. Market Analysis, Insights and Forecast – By Country/Sub-region
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
10. Middle East & Africa Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2019-2030
10.1. Market Analysis, Insights and Forecast – By Technique
10.1.1. Lateral Flow Immunoassay (LFIA)
10.1.2. Agglutination Tests
10.1.3. Flow-through Tests / Immunoconcentration Assays
10.1.4. Molecular Diagnostics
10.1.5. Others
10.2. Market Analysis, Insights and Forecast – By Disease
10.2.1. Human Immunodeficiency Virus (HIV)
10.2.2. Hepatitis B Virus (HBV)
10.2.3. Pneumonia / Streptococcus Associated Infections
10.2.4. Respiratory Syncytial Virus (RSV)
10.2.5. Influenza
10.2.6. Clostridium difficile infection (CDI)
10.2.7. Hepatitis C Virus (HCV)
10.2.8. Methicillin-Resistant Staphylococcus Aureus (MRSA)
10.2.9. Tuberculosis (TB)
10.2.10. COVID-19
10.2.11. Others
10.3. Market Analysis, Insights and Forecast – By End User
10.3.1. Hospital Bedside
10.3.2. Physician's Office Lab
10.3.3. Urgent Care & Retail Clinics
10.3.4. Home & Self-Testing
10.3.5. Nursing Homes
10.3.6. Others
10.4. Market Analysis, Insights and Forecast – By Country/Sub-region
10.4.1. GCC
10.4.2. South Africa
10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Global Market Share Analysis (2022)
11.2. Company Profiles
11.2.1. F. Hoffmann-La Roche Ltd
11.2.1.1. Overview
11.2.1.2. Products
11.2.1.3. SWOT Analysis
11.2.1.4. Recent Developments
11.2.1.5. Strategies
11.2.1.6. Financials (Based on Availability)
11.2.2. Thermo Fisher Scientific Inc.
11.2.2.1. Overview
11.2.2.2. Products
11.2.2.3. SWOT Analysis
11.2.2.4. Recent Developments
11.2.2.5. Strategies
11.2.2.6. Financials (Based on Availability)
11.2.3. Quest Diagnostics Incorporated
11.2.3.1. Overview
11.2.3.2. Products
11.2.3.3. SWOT Analysis
11.2.3.4. Recent Developments
11.2.3.5. Strategies
11.2.3.6. Financials (Based on Availability)
11.2.4. BD
11.2.4.1. Overview
11.2.4.2. Products
11.2.4.3. SWOT Analysis
11.2.4.4. Recent Developments
11.2.4.5. Strategies
11.2.4.6. Financials (Based on Availability)
11.2.5. bioMérieux SA
11.2.5.1. Overview
11.2.5.2. Products
11.2.5.3. SWOT Analysis
11.2.5.4. Recent Developments
11.2.5.5. Strategies
11.2.5.6. Financials (Based on Availability)
11.2.6. Cardinal Health, Inc.
11.2.6.1. Overview
11.2.6.2. Products
11.2.6.3. SWOT Analysis
11.2.6.4. Recent Developments
11.2.6.5. Strategies
11.2.6.6. Financials (Based on Availability)
11.2.7. Cepheid
11.2.7.1. Overview
11.2.7.2. Products
11.2.7.3. SWOT Analysis
11.2.7.4. Recent Developments
11.2.7.5. Strategies
11.2.7.6. Financials (Based on Availability)
11.2.8. Mesa Biotech
11.2.8.1. Overview
11.2.8.2. Products
11.2.8.3. SWOT Analysis
11.2.8.4. Recent Developments
11.2.8.5. Strategies
11.2.8.6. Financials (Based on Availability)
11.2.9. Trinity Biotech
11.2.9.1. Overview
11.2.9.2. Products
11.2.9.3. SWOT Analysis
11.2.9.4. Recent Developments
11.2.9.5. Strategies
11.2.9.6. Financials (Based on Availability)
11.2.10. Quidel Corporation
11.2.10.1. Overview
11.2.10.2. Products
11.2.10.3. SWOT Analysis
11.2.10.4. Recent Developments
11.2.10.5. Strategies
11.2.10.6. Financials (Based on Availability)
11.2.11. Bio-Rad Laboratories, Inc.
11.2.11.1. Overview
11.2.11.2. Products
11.2.11.3. SWOT Analysis
11.2.11.4. Recent Developments
11.2.11.5. Strategies
11.2.11.6. Financials (Based on Availability)
11.2.12. Abbott
11.2.12.1. Overview
11.2.12.2. Products
11.2.12.3. SWOT Analysis
11.2.12.4. Recent Developments
11.2.12.5. Strategies
11.2.12.6. Financials (Based on Availability)
11.2.13. Other Prominent Players

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us